Click here to load reader

Poster ISHRS 2013

  • View
    44

  • Download
    0

Embed Size (px)

Text of Poster ISHRS 2013

  • ACUTE TELOGEN EFLUVIUM IS ASSSOCIATED WITH THE PRESENCE OF FEMALE ANDROGENETIC ALOPECIA

    Potential Therapeutic Implications - A retrospective study of 503 female patients

    RESULTS

    The results of the univariate analysis of ATE FAA association are shown in Table 2. The results of the univariate analysis of

    different therapies on the progression to CTE are shown in Table 3. Both univariate approaches entered binary logistic re-

    gression analysis to identify and select independent predictive factors as related to ATE - FAA association and to CTE pro-

    gression.

    DISCUSSION

    Other authors have proposed five different types of telogen effluvium based on changes in different phases of the follicular

    cycle. But they did not mention any correlation or association of such classification with a different clinical pattern (6): cured

    ATE, association with FAA, or progress to CTE.

    Previous studies have distinguished CTE, from classic acute telogen effluvium by its long fluctuating course, and from FAA by

    its clinical and histological findings (1, 2, 3) and there is also some evidence that Telogen Effluvium may progress rapidly to

    FAA (4).

    The conclusions of our study may be summarized as follows:

    ATE FAA Association Our logistic regression analysis confirmed that Triggering Cause is a significant independent factor

    that predicts association of Acute Telogen Effluvium with Female Androgenetic Alopecia. The triggering causes with higher

    risk of FAA association were: severe diet (10.6 odds ratio), iron deficiency (10.6 odds ratio) and thyroid dysfunction (16.4

    odds ratio) when compared with seasonal hair loss as reference.

    As a consequence, patients suffering ATE may benefit from different therapeutic approaches (depending on the triggering

    cause) to prevent or treat the association with FAA.

    ATE and Progression to CTE Overall 70.2% of patients treated, were cured or experienced significant improvement in less

    than 6 months. Minoxidil use appears to improve the patient outcome with a lower percentage of progression to CTE. Apart

    from treating the precipitating cause, the different additional oral treatments used have not shown any correlation with pro-

    gression to CTE. Patient age seems to be an independent predictive factor of ATE outcome: women with positive outcome

    showed a mean age of 5.1 years less than those with CTE (P